Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt
The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study. Out of them, 260 patients were treated with cefepime or ceftazidime, with...
Main Authors: | Ragaey A. Eid, Marwa O. Elgendy, Ahmed O. El-Gendy, Sara O. Elgendy, Lassaad Belbahri, Ahmed M. Sayed, Mostafa E. Rateb |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/11/1278 |
Similar Items
-
The Impact of Cefepime and Ampicillin/Sulbactam on Preventing Post-Cesarean Surgical Site Infections, Randomized Controlled Trail
by: Mona A. Abdelrahman, et al.
Published: (2023-11-01) -
Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M<sup>Pro</sup> Inhibitor
by: Hani A. Alhadrami, et al.
Published: (2021-06-01) -
Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M<sup>pro</sup>)
by: Ahmed M. Sayed, et al.
Published: (2020-06-01) -
Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
by: Ting-Yi Su, et al.
Published: (2017-07-01) -
Anticoagulants as Potential SARS-CoV-2 M<sup>pro</sup> Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies
by: Ayman Abo Elmaaty, et al.
Published: (2022-10-01)